University of Glasgow: All Types of Heart Failure May Benefit From Treatment With MRAs
September 03, 2024
September 03, 2024
GLASGOW, Scotland, Sept. 3 (TNSres) -- The University of Glasgow issued the following news:
Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure hospitalisation in patients with heart failure and reduced ejection fraction (HFrEF) and also in those with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), according to new research.
The latest study, presented by Professor Pardeep Jhund at the ESC (European Socie . . .
Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure hospitalisation in patients with heart failure and reduced ejection fraction (HFrEF) and also in those with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), according to new research.
The latest study, presented by Professor Pardeep Jhund at the ESC (European Socie . . .